Global News

Roche, Chiasma to develop Octreolin for acromegaly, neuroendocrine tumors

Wednesday, February 20, 2013 09:58 AM

Basel, Switzerland-based Roche and Chiasma, a privately held biopharmaceutical company, have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors.

More... »

Quintiles files registration statement for IPO

Friday, February 15, 2013 05:03 PM

Quintiles Transnational Holdings has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.

More... »

Boehringer Ingelheim selects ChemAxon’s chemistry software

Friday, February 15, 2013 12:11 PM

Boehringer Ingelheim has chosen ChemAxon, a provider of chemistry software solutions and consulting services for life science research, as its provider for a chemistry software platform for multiple applications across R&D, supporting in-house activities and work with external collaboration partners.

More... »

Biocon, Mylan enhance partnership with insulin products collaboration

Friday, February 15, 2013 11:45 AM

Biocon, a biotechnology company based in India, has formed a strategic collaboration with Mylan, a global pharmaceutical company, for for the global development and commercialization of generic versions of its three insulin analog products.

More... »

CTTI forms patient leadership council to drive improvements in clinical trials

Friday, February 15, 2013 10:50 AM

 As part of an effort to improve the way clinical trials are conducted, the Clinical Trials Transformation Initiative (CTTI), a public-private partnership to identify practices to increase the quality and efficiency of clinical trials, has formed a 16-member council to engage patient advocates in its mission.

More... »

Lentigen receives Orphan Drug status for gene therapy for glioblastoma multiforme

Thursday, February 14, 2013 08:00 AM

Lentigen, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced that that the FDA has granted orphan drug status to LG631-CD34, P140K methylguanine methyltransferase (MGMT) transduced human CD34 cells, for bone marrow protection in the treatment of glioblastoma multiforme.

More... »

Dako, Pfizer collaborate on companion diagnostics

Thursday, February 14, 2013 08:00 AM

Dako, a tissue-based cancer diagnostics company based in Denmark, has entered into a collaboration agreement with Pfizer in the field of companion diagnostics.

More... »

Xenon appoints Bridger as executive vice president, R&D

Thursday, February 14, 2013 08:00 AM

Xenon Pharmaceuticals, a clinical genetics-based drug discovery and development company focused on rare diseases, has appointed Gary J. Bridger, PhD, as executive vice president of research and development.

More... »

Genetically engineered virus extends lives of terminally-ill liver cancer patients

Wednesday, February 13, 2013 03:01 PM

A genetically-engineered virus has prolonged the lives of terminally ill liver cancer patients in a small clinical trial, according to the findings published in Nature Medicine. The results will need confirming in larger studies, but Cancer Research U.K. welcomed the advance as "an exciting step forward."

More... »

Reckitt Benckiser, BMS collaborate on Latam OTC

Wednesday, February 13, 2013 02:33 PM

Reckitt Benckiser Group has signed a three year collaboration agreement with Bristol-Myers Squibb (BMS) for a number of market-leading over-the-counter (OTC) consumer health care brands in Brazil, Mexico and certain other parts of Latin America, with an option to purchase at the end of the three year period.

More... »